NCT06842303Recruiting
Contribution of New Pancreatic MRI Sequences for the Evaluation of Tumor Response in Pancreatic Adenocarcinomas
Source: ClinicalTrials.gov · Last updated 17 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Pancreatic adenocarcinoma is the most pessimistic digestive cancer in terms of prognosis. Tumor response assessment is crucial, and the recent development of new magnetic resonance imaging sequences, such as high resolution applied to diffusion sequences (Harder et al., 2022) or magnetic resonance elastography (MRE) (Steinkohl et al., 2021), could help address this issue.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 3 Feb 2025
- Start date
- 6 Jun 2025
- Primary completion date
- 6 Jun 2027
- Lead sponsor
- Central Hospital, Nancy, France
- Diseases
- Pancreatic cancer
- NCT number
- NCT06842303
What you commit to
- Study type: Interventional
- Planned participants: 120
- From 6 Jun 2025 to the primary completion date, 6 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Person deprived of liberty by a judicial or administrative decision, or person undergoing psychiatric care pursuant to Articles L. 32-12-1 and L. 3213-1 of the French Public Health Code.
Other
- Patient with a contraindication to MRI.
- Person referred to in Articles L. 1121-5, L. 1121-7, and L. 1121-8 of the French Public Health Code.
- Pregnant woman, parturient, or breastfeeding mother;
- Minor (non-emancipated) individual;
- Adult individual under legal protection (guardianship, curatorship, or judicial safeguard);
- Adult individual unable to express consent.
Who the study is looking for
- CT scan diagnosis of non-metastatic pancreatic cancer on contrast-enhanced thoraco-abdomino-pelvic CT;
- Adult patient: age ≥ 18 years;
- Patient affiliated with a social security system or beneficiary of such a system;
- Patient who has received complete information about the research organization and has signed an informed consent form.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHRU Nancy Coordinator of this site? Confirm its status | Vandœuvre-lès-Nancy | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.